{"schema_version":"secwatch.filing_event.v1","accession":"0000856982-25-000045","form_type":"8-K","ticker":"MMSI","cik":"0000856982","company_name":"MERIT MEDICAL SYSTEMS INC","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.503064+00:00","generated_at":"2026-05-17T23:23:35.201929+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merit Medical Q2 revenue up 13.2% to $382.5M; non-GAAP EPS $1.01, up 9.8%; appoints new CEO","bullets":["Revenue $382.5M, +13.2% YoY; constant-currency revenue +12.5%, organic constant-currency +6.7%.","GAAP EPS $0.54 (-11.6%), non-GAAP EPS $1.01 (+9.8%); GAAP operating margin 12.3% vs 13.6% prior year.","Non-GAAP operating margin improved to 21.2% from 20.1%; free cash flow $89.1M in H1 2025, +8.1%.","Acquired Biolife (StatSeal/WoundSeal hemostatic devices); no transaction value disclosed.","Martha Aronson named President & CEO, effective Oct 3, 2025; Fred Lampropoulos becomes Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0000856982-25-000045","json":"https://secwatch.observer/filing/0000856982-25-000045.json","markdown":"https://secwatch.observer/filing/0000856982-25-000045.md","text":"https://secwatch.observer/filing/0000856982-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/856982/000085698225000045/0000856982-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/856982/000085698225000045/mmsi-20250730x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:23:35.201929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}